Autolus is a small, cell-therapy biotech with quality metrics below the engine's floor and a rejected analyst target, leaving flat momentum near 52-week lows and a recent earnings-miss pattern as the dominant near-term signals.
Thesis pillars
- Quality Below Engine Floor→Stable
- Rejected Implausible Analyst Target→Stable
- Flat Momentum Near Lows↑Improving
- +2 more pillars — see the Why tab for full reasoning
Autolus Therapeutics plc (AUTL) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $1.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend.
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European... Read more
Sell if holding. Engine safety override at $1.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.7% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $1.50: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $1.40. Score 5.3/10, moderate confidence.
Take-profit target: $1.71 (+14.0% upside). Prior stop was $1.40. Stop-loss: $1.40.
DATA_ISSUE: analyst_target_implausible (raw $8.55 vs price $1.50 — ratio 5.7×). Rejected, falling back to technical TP.; Quality below floor (1.7 < 4.0).
Autolus Therapeutics plc trades at a P/E of N/A (forward -2.5). TrendMatrix value score: 10.0/10. Verdict: Sell.
16 analysts cover AUTL with a consensus score of 4.3/5. Average price target: $9.
What does Autolus Therapeutics plc do?Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory...
Autolus Therapeutics markets AUCATZYL (obe-cel), a CD19-targeted CAR T cell therapy for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia, approved by the FDA in November 2024 and launched in the U.S. in January 2025, with the UK's MHRA and the European Commission granting conditional and full marketing authorizations since. The company posted a $287.5 million net loss in 2025 against a $1,386.8 million accumulated deficit, and expects AUCATZYL to generate substantially all of its product revenue for the foreseeable future.